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Highlights 
 The true incidence of SARS-COV-2 is much higher than the reported number of cases. 
 Large sample size studies showed 1.2-12.9% incidence of SARS-COV-2 among 
asymptomatics. 
 Studies with a small sample size showed up to 87.9% incidence among asymptomatics. 
 Asymptomatic individuals could be a potential source of infection to the community. 
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Abstract 
Background: the recent outbreak of the coronavirus disease 2019 (COVID‐ 19) has 
quickly spread globally since its discovery in Wuhan, China, in December 2019. A comprehensive 
strategy, including surveillance, diagnostics, research, and clinical treatment is urgently needed to 
win the battle against COVID-19. Recently, numerous studies reported the incidence of SARS-
CoV-2 in asymptomatic patients. Yet, the incidence and viral transmission from the asymptomatic 
cases are not apparent yet. Aim: this study aims to systematically review the published literature 
on SARS-CoV-2 in the asymptomatic patients to estimate the incidence of COVID-19 among 
asymptomatic cases, as well as describe its epidemiological and clinical significance. Method: the 
literature was searched through four scientific databases: PubMed, Web of Science, Scopus, and 
Science Direct. Results: a total of 63 studies satisfied the inclusion criteria where the majority of 
the reported studies were from China. However, there was a lack of SARS-CoV-2 epidemiological 
studies from several countries worldwide, tracing the actual incidence of COVID-19, especially in 
asymptomatic patients. Studies with  a large sample size (n>1000) estimated that percentage of 
people contracting SARS-CoV-2 and are likely to be asymptomatic ranges from 1.2-12.9%. 
However, the other studies with a smaller sample size reported a much higher incidence and 
indicated that up to 87.9% of COVID-19 infected individuals could be asymptomatic. Most of 
these studies indicated that asymptopatics are a potential source of infection to the community. 
Conclusion: this review highlighted the need for more robust and well-designed studies to better 
estimate COVID-19 incidence among asymptomatic patients worldwide. The early identification 
of the asymptomatic cases, as well as monitoring and tracing close contact, could help in mitigating 
the spread of COVID-19. 
Keywords: COVID-19, SARS-CoV-2, Asymptomatic carrier, Viruses, Incidence 
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1. Introduction 
Infectious diseases impose a major health threat globally, leading to 15 million deaths 
annually [1]. Although the percentage of mortality due to infectious diseases has declined, 
numerous new infectious diseases have been identified and reported recently. The novel 
coronavirus disease (COVID-19), caused by the SARS-CoV-2 virus, was firstly identified in 
Wuhan, China, in late December 2019 as an outbreak of unusual viral pneumonia [2]. Later, the 
World Health Organization (WHO) declared a public health emergency worldwide, and the total 
number of infected cases reached 4.4 million by May 2020 [3]. Consequently, educational 
institutions, business centers, public transport, and other social interaction were locked down 
points to prevent the spread of COVID-19 and ease the burden on health facilities. SARS-CoV-2 
is an enveloped positive-sense single-stranded RNA virus with six open reading frames (ORFs) 
that codes for structural proteins, including surface (S), envelope (E), membrane (M), and 
nucleocapsid N proteins [4]. Based on the genomic structures and phylogenetic analysis of SARS-
CoV-2, the virus belongs to genera Betacoronavirus, which includes SARS-CoV and MERS-CoV. 
Yet, SARS-CoV-2 has differences in its genomic that can influence its pathogenesis.  
The most effective approach to prevent and mitigate the adverse consequences of this viral 
pandemic requires the development of effective surveillance programs, incorporated with 
laboratory preparedness. Diagnostic laboratory tests play a significant role in the rapid and 
accurate detection of new viruses [5, 6]. Currently, real-time reverse-transcription polymerase 
chain reaction (RT-PCR) testing is the main technique used for the diagnosis of COVID-19. 
However, false-negative RT-PCR results occur in up to 30% of COVID-19 patients [7-9]. This 
could be due to the collection of inappropriate or insufficient sample, inaccurate conditions of 
sample transportation and storage, as well as collecting the sample too late in the disease process. 
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On the other hand, serology testing could cover this gap since detecting SARS-CoV-2 IgG 
antibodies could indicate recovery or immunity from COVID-19 infection. Besides, IgM could be 
detected in the acute phase of infections. Although, manual enzyme-linked immunoassay (ELISA) 
kits could be subjected to non-specific binding and cross-reactivity with other coronaviruses such 
as MERS-CoV and SARS-CoV-1, most commercially available antibodies utilize lateral flow 
assays (LFA) [10]. However, recently ELISA and automated-based assays were also introduced. 
The diagnostic performance, including sensitivity and specificity, of these assays, were better than 
the LFA [11].  It worth mentioning that there is a high percent of COVID-19 asymptomatic patients 
who could transmit the infection to all communities. For instance, the asymptomatic ratio of 
COVID-19 was estimated to be 41.6% of Japanese individuals who were evacuated from China 
[12]. Similarly, 72% of people infected with COVID-19 on board the Diamond Princess cruise 
ship were asymptomatic [13]. However, the extent of viral transmission from the asymptomatic 
cases is not clear yet. The positive RT-PCR results only imply the potential infectivity. A 
prospective study was published on March 28 in which the viral load and clinical manifestations 
of 2,147 close contacts of symptomatic and asymptomatic COVID-19 cases were followed up [15]. 
The study concluded that the virus infection rate of close contacts with asymptomatic patients was 
4.11%.  
Since the transmission ability of asymptomatic individuals should not be ignored, it was of 
interest to conduct a systemic review to paint a picture of the current status and incidence of SARS-
CoV-2 in asymptomatic patients. Therefore, this study would give significant insights into 
COVID-19 infection and help health authorities to determine the need for social distancing close 
contact restrictions in specific areas or populations. 
2. Methods 
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2.1. Search Strategy 
We conducted a systematic review of all literature published on COVID-19 in the 
asymptomatic patients using four databases: PubMed, Web of Science, Scopus, and ScienceDirect. 
The search covered all literature within the databases up to April 2020. The databases were queried 
with the keywords: “COVID-19”, “SARS-CoV-2”, “seroprevalence”, and “asymptomatic” to 
ensure complete coverage of all literature. The four databases were searched without filters. 
Therefore, results that were letters and commentaries were also included. All retrieved citations 
were imported into EndNote X8, and duplicates were removed using the EndNote X8 built-in 
“Find Duplicates” feature. Finally, the titles and abstracts of the remaining citations were screened 
to remove any irrelevant articles. 
2.2. Study Selection 
The following inclusion criteria were used in study selection: (i) published in a peer-
reviewed journal, letters, case reports, and commentaries (ii) articles studying the COVID-19 
infection in asymptomatic patients, and (iii) articles published in English or at least with an abstract 
in English. A schematic of the search strategy and study selection process is shown in Figure 1. 
Besides, studies that reported the coinfection of COVID-19 with other viruses as well as 
comorbidities, such as cancer and cystic fibrosis, were also included in this study. No exclusion 
criteria were followed unless the studies did not report the incidence of SARS-CoV-2 in 
asymptomatic patients, published in a non-English language, or do not have full-text access. 
2.3. Data Extraction and Analysis 
The studies included in this systematic review were analyzed two times by the same 
individual to ensure accurate capture of the information. The analyzed data included the incidence 
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of SARS-Cov-2 in the asymptomatic COVID-19 patients, incidence of COVID-19 infection, 
routes of transmission, laboratory diagnostic tests, laboratory results, as well as CT scan findings.  
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Figure 1. Flow diagram of the search strategy and article selection.  
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3. Results 
3.1 Search findings 
The search yielded 505 studies, of which 370 citations remained after removing duplicates 
(Figure 1). After screening the titles, abstracts, and keywords, 312 citations were excluded. The 
removed citations included irrelevant studies. The remaining 67 citations were screened against 
the eligibility criteria. Of these, one study was removed due to the unavailability of full-text access. 
Furthermore, three studies were removed two for being published in languages other than English 
with no English abstract. The remaining 63 studies were included in this study for further analysis, 
and they consisted of letters to the editor, commentaries, case reports as well as research studies. 
3.2 Epidemiological findings 
The reviewed studies covered SARS-CoV-2 incidence worldwide. Country-wise, the 
majority of the studies were from China (n = 44) and included different provinces such as Wuhan, 
Shenzhen, Guangzhou, Beijing, Shanghai, Hunan, Nanjing, Guangdong, Anhui, Hubei, Zhejiang, 
Jinan, and Hefei (Table 1). The remaining studies were published in Japan (n = 2), Italy (n = 3), 
Germany (n = 1), Iran (n = 2), and USA (n = 6), which included studies from Texas, Washington, 
and New York. However, there was a lack of SARS-CoV-2 epidemiological studies from several 
countries worldwide, tracing the actual incidence of COVID-19, especially in asymptomatic 
patients.  
Looking at all the included studies with a large sample size (n>1000 cases), these studies (Table 
1, highlighted with bold text) estimated that percentage of people contracting SARS-CoV-2 and 
are likely to be asymptomatic range from (1.2-12.9%). However, the other studies with a smaller 
sample size (n<1000) reported a much higher incidence and indicated that up to 87.9% of 
COVID-19 infected individuals could be asymptomatic (Table 1). Most of these estimates were 
based on RT-PCR results. On the other hand, the estimated seroprevalence of antibodies to 
SARS-CoV-2 was reported to be higher. For instance, a study that was performed on 2,857 blood 
donors from Rio de Janeiro showed 23.7% of IgM positive cases, 11.4% of IgG positive cases, 
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while both IgM and IgG was detected in 64.9% [16]. This is could due to the limitation of the 
nasal swab since the PCR diagnostic could be negative though antibody detection is positive. In 
fact, this finding was reported in a study where four subjects out of 317 asymptomatic 
participants had negative PCR diagnostic, while antibody testing was positive [17]. Therefore, 
relying only on molecular testing could significantly underestimate the seroprevalence SARS-
CoV-2, especially in asymptomatic individuals. 
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4. Discussion 
The spread of COVID-19 is an emerging condition with pandemic potential that threatens 
all countries. Over the last four months, more than three million cases of COVID-19 have been 
confirmed worldwide. Numerous epidemiologic investigations identified an association with 
respiratory droplet transmission. Yet, understanding of the transmission risk is incomplete. It worth 
mention that COVID-19 asymptomatic individuals may pose a significant public health threat. The 
majority of these patients might be unaware of their disease and, therefore, not isolate themselves 
or seek treatment. Consequently, unknowingly transmit the virus to others. To the best of our 
knowledge, this is the first systematic review study that investigated the incidence of SARS-CoV-
2 in asymptomatic patients.  
A total of 63 out of 505 screened studies reporting COVID-19 asymptomatic patients were 
included in this review. Epidemiological data, clinical laboratory results, CT image findings, as 
well as the medical and contact history of the patient are critical knowledge that should be carefully 
studied when a new infectious disease emerged [59]. Although asymptomatic patients with SARS-
CoV-2 were uncommon, studies showed that the prevalence of SARS-CoV-2 in asymptomatic 
patients is underestimated and might increase. For instance, a review paper showed the rate of 
asymptomatic individuals with the Middle East Respiratory Syndrome coronavirus (MERS-CoV) 
ranged from 0% to 28.6% [60]. Besides, it was reported that 75% of COVID-19 infected 
individuals could be asymptomatic [55]. 
COVID-19 infection ranges from asymptomatic to severe respiratory distress. Yet, 
clinically is shows a milder infection in children, and many studies reported children patients with 
asymptomatic COVID-19 infection. For instance, a study in China (Guangzhou) reported an 
asymptomatic 3-years old male who tested positive for SARS-CoV-2, yet, had normal lymphocyte 
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counts and chest CT images [19]. Similarly, a study reported in China (Wuhan) showed a 3-years 
old male asymptomatic patient with positive RT-PCR for SARS-CoV-2 and normal lymphocyte 
counts and chest CT images [20]. It is unknown yet the reason of having a benign clinical course 
and low incidence of COVID-19 in children compared to adults. A proposed hypothesis suggested 
that it might be due to the low expression of ACE2 receptors, high plasticity of their immune 
system, or to the exposure of other coronaviruses which are generally common in kids [61, 62]. 
Besides, children may play a major role in community-based viral transmission. For instance, it 
was reported that viral shedding in the stool sample could persist for several weeks after diagnosis 
[63, 64]. Consequently, it poses a threat of viral transmission through the fecal-oral route, 
particularly for infants and children who are not toilet trained. Most of the reported COVID-19 
cases in children were due to close contact with family members with SARS-CoV-2 infection 
(Table 1). Many experts believe that undetermined asymptomatic cases of COVID-19 infection 
could be an important source of contagion [41]. Therefore, the early identification of the 
asymptomatic cases, as well as monitoring and tracing close contact, could help in mitigating the 
spread of COVID-19 infection. 
Another factor that increases the asymptomatic rate of COVID-19 is the inaccuracy of 
diagnostic testing. For instance, a recent article highlighted key important steps to be considered 
when designing seroprevalence studies, as well as experts’ opinion on the recent studies. A major 
concern raised about the recently published results was the type of antibody test used since most 
of them inaccurate to support the conclusions [65]. It was reported that the manual ELISA kits are 
subject to cross-reaction with other coronaviruses such as SARS-CoV-1 and MERS-CoV [10]. 
This depends on the type of antibody or antigen used to coat the plates. For instance, a recent study 
used previously developed ELISA method based on bat SARS-CoV Rp3 N protein since it does 
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not cross-react with other human coronaviruses except SARS-CoV [66]. The method successfully 
detected IgM and IgG antibodies against SARS-CoV-2 in early cases of COVID-19. Yet, various 
studies, such as the studies included in this review, used Chinese manufactured tests kit that are 
not approved by Chinese authorities or the US Food and Drug Administration (FDA). Besides, 
until to date, a seroprevalence population-based study was carried in Santa Clara County, USA 
and suggested that over 30% of positive cases are missed by the PCR test and results in an 
underestimation of the incidence. The most significant implication of their findings is that the true 
infection rate is much higher than the reported number of cases. For instance, the study showed 
that the infection was 50 to 85-fold higher than confirmed positive cases by PCR [67]. Besides, 
although most of the included articles in this study used RT-PCR to confirm asymptomatic cases, 
no serological or other tests were performed to accurately estimate the incidence of SARS-CoV-2 
in asymptomatic patients.  In other words, PCR is considered the gold standard for diagnosis. Yet, 
if the sample was collected after 14 weeks or more after infection, the viral genome/antigen might 
not be detected. Therefore, it could underestimate the prevalence of the infection.  
Besides, some of the included studies reported that the patients were positive for SARS-
CoV-2 IgG, which suggested that the patient was an asymptomatic SARS-CoV-2 carrier. The 
differential use of serology for confirming acute infection is not appropriate without the additional 
collaboration of results. Therefore, combining both molecular and serological testing would be the 
best approach to accurately estimate the prevalence of COVID-19 infection, especially if the 
patient is at later stages of the infection and does not show symptoms [68]. 
Although governments in many countries are planning to conduct largescale 
seroprevalence surveys, many laboratories try to rely on well-established and validated lab tests, 
rather than rapid tests. The latter is based on blood collected from finger pricks to detect SARS-
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CoV-2 antibodies. Yet, the test performance and efficacy are not up to the required level, and many 
false results were detected. Both specificity and sensitivity are essential in detecting SARS-CoV-
2 to prevent false positive and negative results. It is not reliable to examine the test performance 
and efficacy of rapid tests based on finger-prick blood compared to the ELISA test, which utilizes 
collect venous blood. Consequently, preventing the underestimation of asymptomatic COVID-19 
infection rate. 
Such positive cases may contribute to the silent spread of the virus. Yet, one of the 
significant limitations of many studies reporting asymptomatic cases is the difficulty of 
differentiating between asymptomatic or pre-symptomatic, who are asymptomatic at the time of 
testing and later on they developed symptoms. Citing data from China WHO officials said on April 
1 “some cases of asymptomatic carriers have been confirmed by finding and testing people who 
were in close contact with COVID-19 patients. For those who tested positive without symptoms, 
follow-up exams confirmed that about 25% continued to show no signs”. For instance, a clinical 
study with a small sample size from china, done in March 2020, followed up 24 asymptomatic 
positive PCR patients, 60% of them were pre-symptomatic and showed COVID-19 symptoms 
after 1-3 weeks [31].  More follow-up studies should be done to determine whether these cases 
continue to be asymptomatic or eventually develop symptoms. Whether these asymptomatic or 
pre-symptomatic individuals can spread the infection, a question remained to be answered with 
further follow-up studies.   
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5. Conclusion 
COVID-19 is a new infectious disease that infected more than three million people in many 
countries all over the world. The severity and clinical manifestation of COVID-19 varies, and some 
individuals were reported as asymptomatic. Based on the results of this study, many of the COVID-
19 infected cases show no symptoms, and that the infection could be transmitted during the 
incubation period. Consequently, asymptomatic patients are considered carriers and a potential 
source of infection to the community. Therefore, additional research studies on the 
epidemiological significance of COVID-19 asymptomatic cases are required. 
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 Table 1: Characteristics and summary data of included studies 
Country 
Type of the 
study 
Total 
case 
number 
Number of 
asymptomatic 
patients 
Age/mean age Gender Clinical features Chest CT findings Reference 
China 
(Guangzhou ) 
Correspondence 295 45 (15.2%) - - RT-PCR positive for SARS-CoV-
2. 30 patients started to show few 
clinical symptoms (after 3-14 
days). 
Persistent negative CT 
findings. 15 patients had 
CT scan positive (after 3–
6 days) for COVID-19 
pneumonia. 
[18] 
China 
(Guangzhou ) 
Correspondence 5 2 (40%) 3-years old male 
33-years old 
woman 
1 male 
1 female 
Normal lymphocyte counts.  
Positive qRT-PCR results. 
Normal chest CT images  [19] 
China 
(Guangzhou) 
Research letter - 7 Age range: 21-
56-year-old 
4 males 
3 females 
Positive for SARS-CoV-2 by RT-
PCR 
The 56-year old patient 
showed multiple ground-
glass-like high-density 
shadows on both lungs. 
[20] 
China 
(Guangdong ) 
Research article 
(familial 
cluster) 
5 1 (20%) 10-year-old Male  RT-PCR positive for SARS-
CoV-2. Lymphopenia, 
thrombocytopenia, and increased 
Ground-glass lung 
opacities 
[21] Jo
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C-reactive protein and lactate 
dehydrogenase levels 
China 
(Wuhan ) 
Research article - 58 The average age 
of patients was 
42.60±16.56 
years old 
26 male 
and 32 
females 
After a short-term follow-up, 16 
patients (27.6%) presented 
symptoms with lower lymphocyte 
count and higher CRP, mainly 
including fever, cough, and 
fatigue 
Ground glass opacity 
(GGO) in 55 (94.8%) with 
peripheral in 44 (75.9%) 
distribution, unilateral 
location in 34 (58.6%) and 
mostly involving one or 
two lobes in 38 (65.5%) 
[22] 
China 
(Wuhan) 
Research letter 
(familial 
clsture) 
- 5 37-year-old wife 
7-year-old 
fraternal twins 
62-year-old 
grandfather 
64-year-old 
grandmother 
2 females 
1 male 
Twins 
gender not 
determined 
Throat swab specimens tested for 
SARS-CoV-2 were positive by 
PCR except for one patient, who 
tested negative on 4 consecutive 
throat swab specimen tests for 
SARS-CoV-2 but whose stool 
specimen was positive for SARS-
CoV-2 
Abnormal chest CT scans 
showing features 
consistent with SARS-
CoV-2 infection in one of 
the twins 
[23] 
China 
(Wuhan) 
Case report - 1 (diagnosed as 
advanced lung 
adenocarcinoma) 
56-years Male RT-PCR of SARS-CoV-2 and 
IgM were negative, while his 
serological IgG antibody to 
SARS-CoV-2 were positive 
CT scan was negative [24] Jo
urn
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China 
(Wuhan) 
Case report - 1 8-year-old Female No clinical symptoms or 
decreased lymphocyte count. 
Positive for SARS-CoV-2 IgG. 
Normal chest CT image [25] 
China 
(Wuhan) 
Research 
article 
1012 30 (3%) The median age 
50-year old 
ranging from 16 
to 89 years 
- Positive RT-PCR for SARS-
CoV-2. During follow up from 
admission to the end, fever 
occurred in 6, with cough in 8, 
myalgia in 3, dyspnoea in 2, 
nasal congestion in 1, and 
abdominal pain in 1. 14 of 1012 
patients (1.4%) remained 
asymptomatic during the whole 
follow up 
Small patchy opacities 
(38.7%) and ground-
glass opacities (55.4%) 
[26] 
China 
(Wuhan) 
Research article 155 51 (33%) - - Positive RT-PCR for SARS-CoV-
2 
CT showed no signs of 
viral pneumonia 
[27] 
China (Hubei) Letter to the 
Editor 
- 25 Average age 42.2 
(28–73) 
17 males 
8 females 
16 of the patients recovered 
without any symptoms. Nine 
patients developed a mild cough 
and/or other symptoms. 
Two-thirds of the patients 
had involvement of a 
single lobe, and two-thirds 
had only a ground-glass 
density shadow. The least 
common CT finding was 
[28] 
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interlobular septal 
thickening 
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China (Hubei) Case report - 1 3 months Male  No nasal congestion and snot, no 
cough, no shortness of breath, no 
cyanosis, no nausea, vomiting, 
and diarrhea, good mental 
response, and crying sound. All 
blood, liver, and kidney tests were 
normal. RT-PCR positive for 
SARS-CoV-2 
Chest X-ray showed a 
slightly thicker texture of 
the right lung 
[29] 
China 
(Shanghai) 
Letter to the 
Editor 
328 13 (3.9%) Mean age was 
51.8 years 
(range: 25-80 
years). 
6 males 
7 females 
Leucocytes were below the 
normal range in two patients 
(15.4%). Ten patients (76.9%) 
had differing degrees of elevation 
of the ESR. Liver function, renal 
function, and coagulation function 
were within the normal range. No 
fever. Positive RT-PCR for 
SARS-CoV-2 
A patient has developed 
signs, such as pneumonia 
on chest CT 
[30] 
China 
(Nanjing) 
Research article - 24 screened due 
to  close 
Contact with 
COVID-19 
patients 
Cases with 
symptoms after 
diagnosis (n=5) 
53.0 (23.0 -65.0) 
8 males 
and 16 
females 
Five cases (20.8%) developed 
symptoms (fever, cough, fatigue, 
etc.) during hospitalization. 5 
(20.8%) presented stripe 
shadowing in the lungs. The 
Twelve (50.0%) cases 
showed typical CT images 
of the ground-glass chest 
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Cases without 
symptoms after 
diagnosis (n=19) 
32.0 (15.0 - 57.0) 
remaining 7 had no symptoms 
during hospitalization. 
4 patients had C-reactive protein 
level ≥10 mg/liter 
China 
(Hunan) 
Research article 78 2 (2.5%) 36-year-old 
19-year-old 
Males 
 
Positive RT-PCR for SARS-CoV-
2. Patient 1: Laboratory 
evaluation showed an elevated 
myoglobin, ALT, and uric acid 
level. Patient 2: Laboratory tests 
including blood routine test, 
erythrocyte sedimentation rate 
(ESR), C-reactive protein and 
three items of myocardial enzyme 
spectrum were all negative 
Chest CT scan was 
negative for both 
[32] 
China 
(Guangdong) 
Short 
communication 
- 3 - Patient 1: 
not 
determined 
Patient 2: 
female 
Patient 3: 
male 
No fever, cough, and 
expectoration during 
hospitalization. 
Patient 1: multiple patchy 
and ground glass shadows 
with uneven density and 
fuzzy edge in the outer 
zone of both lungs 
[33] 
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China (Anhui) Short 
communication 
- 1 22‐ year‐ old 
pregnant woman 
Female No cough, dyspnea, or diarrhea 
was noted. 
CT reexamination showed 
a small amount of pleural 
effusion on both sides 
[34] 
China 
(Zhejiang) 
Research article 
(observational 
cohort study) 
36 10 (28%) Age range: 0–16 
years with mean 
8·3 years 
- Decreased lymphocytes, high 
levels of procalcitonin, D-dimer, 
and creatine kinase MB 
-  [35] 
China (Hefei) Prospective 
contact-tracing 
study 
- 1 22-year-old Male - Lung infiltrates [36] 
China (Jinan) Research article 47 11 (23.4%) Median age: 23 
years, ranging 
from 1 to 60 
years 
6 males 
7 females 
Pharyngeal swab COVID-19 
nucleic acid was positive. The 
blood cell test results showed that 
27. 3% (3/11) had decreased 
white blood cell and 36.4% (4/11) 
had increased lymphocyte count. 
High D-dimmer levels, C-reactive 
protein and ESR. 
4 (36.4%) showed bilateral 
involvement and 3 
(27.3%) showed unilateral 
involvement 
[37] 
China Research 
article 
2143 94 (12.9%) Median age: 7 
years (range: 2-
13). 
- No clinical symptoms and signs, 
while the 2019-nCoV nucleic 
acid test is positive. 
The chest imaging is 
normal. 
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China Clinical 
observations 
83 1 (1.2%) 50-year old Female Persistent positivity of the virus 
nucleic acid in her throat swabs 
and anal swabs for at least. 
17 days suggested that she was 
very likely a healthy carrier. 
- [39] 
China  Research article 
(familial 
cluster) 
5 2 (40%) 28-year-old 
23-years old 
Males Patients were afebrile without any 
clinical signs. On days 3 through 
5 of hospitalization, the 23-years 
old man developed fever and 
cough symptoms. Other 
laboratory examinations showed 
increasing C-reactive protein 
Chest CT images showed 
no abnormalities 
On days 3 through 5 of 
hospitalization, the 23-
years old man chest CT 
scans showed ground-
glass opacities in the lungs 
[40] 
China  News journal 
article 
166 130 (78%) - - - - [41] 
China  Research article 21 5 (20.8%) 25 (10–61) years 3 males 
3 females 
RT-PCR positive for SARS-CoV-
2. Only 1 case generated SARS-
CoV-2 specific antibody 
responses. 
- [42] 
China  Research 
article 
72,314 889 (1.2%) Most were aged 
30–79 years 
- Positive viral nucleic acid test 
results but without any 
COVID19  symptoms 
- [43] Jo
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China  Research article 
(hospitalized 
patients) 
- 26 median age is 
29.5 years 
16 males 
10 females 
 RT-PCR positive for SARS-
CoV-2. C-reactive protein and 
lymphocytes count were normal 
in all patients. Three patients had 
reduced albumin and  two patients 
with slightly elevated creatinine 
levels 
Nine patients with normal 
CT scans, 10 patients with 
typical manifestations 
(patch-like, ground-glass 
opacities distributed in the 
extrapulmonary zone), 
seven patients with 
changes in a unilateral 
lung, and three patients 
with changes in bilateral 
lungs. 
[44] 
China  Familial cluster 
study 
8 3 (37.5%) 35-year-old 
53-year-old 
3-month-old 
infant 
Female RT-PCR positive for SARS-CoV-
2. No clinical symptoms 
Ground-glass opacities 
except in the infant 
[45] 
China  Research letter 6 1 (16.6%) 20-year-old Female RT-PCR positive for SARS-CoV-
2. No elevated temperature 
measured or self-reported fever 
and no gastrointestinal or 
respiratory symptoms, including 
cough and sore throat, reported or 
observed by the physicians. 
Normal chest CT image [46] 
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Japan (Cruise 
Ship) 
Rapid 
communication 
634 328 (51.7%) Female: age 
ranged 0–59 
years. Males: not 
determined 
313 female 
321 male 
SARS-CoV-2 positive by PCR  - [14] 
Japan  Research article 112 38 (33.9%) Age ranged 
(61.5–73.75) 
years 
22 females 
16 males 
RT-PCR positive for SARS-CoV-
2. IgM was detected in 27.8%, of 
the specimens collected and IgG 
was detected in 3.3%, 
Chest CT showed 
abnormal lung findings 
consistent with the 
radiographic features of 
COVID-19 in 22 (57.9 %). 
[47] 
USA (Texas) Case report - 1 63-year-old Female SARS-Cov2 nasopharyngeal 
swab RT-PCR resulted positive. 
No respiratory symptoms, normal 
body temperature, no recent travel 
CT-simulation scan  
revealed interval 
development of new 
multifocal ground-glass 
opacities of the lungs 
[48] 
USA 
(Washington) 
Research article 48 27 (56%) Age mean 75.9 14 females 
13 males 
real-time reverse-transcriptase 
polymerase chain reaction (rRT-
PCR) to test all samples. 15 
reported no symptoms and 12 
reported only stable chronic 
symptoms. Fifteen (56%) 
residents who were asymptomatic 
- [49] 
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at the time of testing had 
documented cognitive impairment 
USA 
(Washington ) 
Synopsis 23 13 (57%) Age mean 80.7 - The reverse transcription–
polymerase chain reaction (RT-
PCR) testing cycle threshold (Ct) 
values indicated large quantities 
of viral RNA 
- [50] 
USA 
(Washington) 
Editorial 48 27 (56%) - -  RT-PCR positive for SARS-
CoV-2 
- [51] 
USA (New 
York) 
News journal 
article 
33 
 
29 (87.9%) - Pregnant 
Females 
 RT-PCR positive for SARS-
CoV-2 
- [52] 
USA (New 
York) 
Case series 43 14 (32.6%) Maternal age 
ranged from 20 
to 39 years with a 
mean age of 26.9 
years old 
Pregnant 
females 
PCR-confirmed SARS-CoV-2 
8 patients developed fever 
ranging from 37.9°C to 39.2°C 
during admission in the hospital. 
- [8] 
Italy (Brescia) Report 
(Incidental 
Findings) 
Patients 
with 
different 
types of 
cancer 
7  Median age 64.6 
years old (Range: 
55-79) years 
 
2 males 
5 females 
RT-PCR positive for SARS-CoV-
2 
Patient 3: chest CT 
showed a suspicious 
retrosternal lymph node 
but no lung pathology. 
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Patient 5: Thoracic CT 
displayed several ground-
glass opacities in the right 
lung. 
Patient 7: CT showed 
diffuse interstitial 
pneumonia with peripheral 
ground-glass opacities 
Italy  Case report - 1 1 month Male  Real-time PCR confirmed 
infection 
The infant is a cystic fibrosis 
patient. He never developed a 
fever or any signs of infection. 
- [54] 
Italy News journal 
article 
3300 90 (2.7%) - -  RT-PCR positive for SARS-
CoV-2 
- [55] 
Germany  Correspondence - 4 Patient 1: 33-
year-old 
Patient 1: 
male 
 RT-PCR positive for SARS-
CoV-2 
- [56] 
Iran (Tehran) Case report - 1 44-year-old Male   RT-PCR positive for SARS-
CoV-2 
 
Patchy ground-glass 
opacity in the upper lobe 
of the right lung 
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Iran  Case report multiple 
trauma 
patients 
admitted 
to 
hospital 
8 49.71 ±13.13 
(range: 34–67) 
years 
62.5% 
male 
None of the patients had COVID-
19 symptoms at the time of 
admission to the hospital. 
RT-PCR positive for SARS-CoV-
2. Laboratory results showed 4 
(50%) patients with slight 
increase in C-reactive protein 
Pneumonia in chest CT 
scan  
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